New Topics in Vasopressin Receptors and Approach to Novel Drugs: Role of the Vasopressin Receptor in Psychological and Cognitive Functions
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Arginine vasopressin (AVP) is a neurohypophyseal peptide best known as an antidiuretic hormone. AVP receptors have been classified into three subtypes: V1a, V1b, and V2 receptors. V1a receptor (V1aR) and V1b receptor (V1bR) are widely distributed in the central nervous system, including the septum, cortex, hippocampus, and hypothalamus. Clinical studies have demonstrated an involvement of AVP in psychiatric disorders. In the present study, we examined the performance of V1aR or V1bR knockout (KO) mice compared to wild-type (WT) mice in behavioral tests. V1aR and V1bR KO mice exhibited deficits of social behavior and prepulse inhibition in comparison to WT mice. Moreover, V1aR KO mice exhibited reduced anxiety-like behavior and impairment of spatial learning. These results suggest that V1aR and V1bR play an important role in psychological and cognitive functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamatergic mechanisms in schizophrenia
Tsai, G., & Coyle, J. T. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082701.160735 · Cited by 577
Bielsky, I. F., Hu, S.-B., Szegda, K. L., Westphal, H., & Young, L. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300360 · Cited by 531
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Bielsky, I. F., Hu, S.-B., Ren, X., Terwilliger, E. F., & Young, L. J. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.031 · Cited by 367
Sex-specific influences of vasopressin on human social communication
Thompson, R. R., George, K., Walton, J. C., Orr, S. P., & Benson, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600406103 · Cited by 312
Vaccari, C., Lolait, S. J., & Ostrowski, N. L. (1998) · Endocrinology · doi:10.1210/endo.139.12.6382 · Cited by 308
Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
Kim, S.-J., Young, L. J., Gonen, D., Veenstra-VanderWeele, J., Courchesne, R., Courchesne, E., Lord, C., Leventhal, B. L., Cook Jr, E. H., & Insel, T. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001125 · Cited by 265
Neuropeptides and the evolution of social behavior
Insel, T. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00146-x · Cited by 264
Yirmiya, N., Rosenberg, C., Levi, S., Salomon, S., Shulman, C., Nemanov, L., Dina, C., & Ebstein, R. P. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001812 · Cited by 232
Examination of AVPR1a as an autism susceptibility gene
Wassink, T. H., Piven, J., Vieland, V. J., Pietila, J., Goedken, R. J., Folstein, S. E., & Sheffield, V. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001503 · Cited by 212
The involvement of the vasopressin system in stress-related disorders
Landgraf, R. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359664 · Cited by 127
Distribution of messenger RNA for the vasopressin V1a receptor in the CNS of male and female rats
Szot, P., Bale, T. L., & Dorsa, D. M. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90111-2 · Cited by 125
Meynen, G., Unmehopa, U. A., van Heerikhuize, J. J., Hofman, M. A., Swaab, D. F., & Hoogendijk, W. J. G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.12.010 · Cited by 108
Distribution and developmental change of vasopressin V1A and V2 receptor mRNA in rats
Hirasawa, A., Hashimoto, K., & Tsujimoto, G. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90226-7 · Cited by 78
Patterns of ACTH Secretagog Secretion in Response to Psychological Stimuli
Romero, L. M., & Sapolsky, R. M. (1996) · Journal of Neuroendocrinology · doi:10.1046/j.1365-2826.1996.04441.x · Cited by 77
V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze
Egashira, N., Tanoue, A., Higashihara, F., Mishima, K., Fukue, Y., Takano, Y., Tsujimoto, G., Iwasaki, K., & Fujiwara, M. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2003.11.050 · Cited by 69
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Dumais, K. M., & Veenema, A. H. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2015.04.003 · Cited by 520
Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems
Koshimizu, T.-A., Nakamura, K., Egashira, N., Hiroyama, M., Nonoguchi, H., & Tanoue, A. (2012) · Physiological Reviews · doi:10.1152/physrev.00035.2011 · Cited by 407
Self-citationBehavioral and endocrine effects of chronic exposure to low doses of chlorobenzenes in Wistar rats
Nagyeri, G., Valkusz, Z., Radacs, M., Ocsko, T., Hausinger, P., Laszlo, M., Laszlo, F. A., Juhasz, A., Julesz, J., & Galfi, M. (2012) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2011.09.011 · Cited by 17
Metadata
- Authors
- Egashira, N., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M.
- Venue
- Journal of Pharmacological Sciences
- Publisher
- Japanese Pharmacological Society
- Published
- 2009
- Volume
- 109
- Issue
- 1
- Pages
- 44-49
- ISSN
- 1347-8613 (ISSN-L)
- 1347-8648
- OpenAlex
- W2052363965
- Cited by
- 56
- References
- 19
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.